Can I read Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial on EtoBox?

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial by Pollock, Carol; Stefánsson, Bergur; Reyner, Daniel; Rossing, Peter; Sjöström, C David; Wheeler, David C; Langkilde, Anna Maria; Heerspink, Hiddo J L is a Medicine article available to read on EtoBox.

What is Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial about?

## Background: In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. we assessed the albuminuria-lowering effect of the sodium-glucose co-transporter-2 inhibitor dapagliflozin with and without the dipeptidyl peptidase-4 inhibitor saxagliptin, and the effect of dapagliflozin-saxagliptin on glycaemic control in patients with type 2 diabetes and moderate-to-severe chronic kidney disease. ## Methods: In this double-blind, placebo-controlled trial (delight), we enrolled patients at 116 research centres in australia, canada, japan, south korea, mexico, south africa, spain, taiwan, and the usa. we included patients with a known history of type 2 diabetes, increased albuminuria (urine albumin-to-creatinine ratio [uacr] 30-3500 mg/g), an estimated glomerular filtration rate of 25-75 ml/min per 1·73 m, and an hba of 7·0-11·0% (53-97 mmol/mol), who had been receiving stable doses of angiotensin-converting enzyme inhibitor or angiotensin ii receptor blocker therapy and glucose-lowering treatment for at least 12 weeks. after a 4-week, single-blind placebo run-in period, participants we

Who reads Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial?

Author

Pollock, Carol; Stefánsson, Bergur; Reyner, Daniel; Rossing, Peter; Sjöström, C David; Wheeler, David C; Langkilde, Anna Maria; Heerspink, Hiddo J L

Publisher

Elsevier ; The Lancet Publishing Group; Elsevier BV (ISSN 2213-8587)

Published

2019

Language

EN

Field

Medicine (Health Sciences)